Publication | Closed Access

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

Hematological MalignancyChronic Myeloid LeukemiaMedicineHematologyPathologyImatinib Plasma LevelsStandard-dose ImatinibAdult T-cell Leukemia-lymphomaOncologyCancer ResearchMyeloid Neoplasia